Loading...
•
Dec 31, 2021
Vera Q4 2021 Earnings Report
Vera Therapeutics reported its business highlights and financial results.
Key Takeaways
Vera Therapeutics reported a net loss of $16.8 million for the fourth quarter of 2021, with $79.7 million in cash and cash equivalents as of December 31, 2021. The company highlighted the progress of its clinical trials for atacicept and MAU868, and the strengthening of its balance sheet through an equity offering.
Phase 2b ORIGIN clinical trial of atacicept is on track, with topline data expected in Q4 2022.
MAU868 was acquired, a first-in-class monoclonal antibody to treat BK Virus infections, with full results from interim analysis of Phase 2 study of MAU868 in kidney transplant recipients planned for mid-2022.
Initiation of Phase 3 pivotal clinical trial of atacicept in lupus nephritis is planned for 2H-2022.
The balance sheet was strengthened by completing an equity offering with net proceeds of approximately $80.2 million in February 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...